Katalog der Deutschen Nationalbibliothek

Ergebnis der Suche nach: "Originator"
im Bestand: Gesamter Bestand

111 - 120 von 136

	111	Evaluation of adverse events focusing on infection associated with infliximab originator and biosimilar using a spontaneous reporting system database Enthalten in Journal of pharmaceutical health care and sciences Bd. 5, 7.10.2019, Nr. 1, date:12.2019: 1-4
	112	Forced Degradation Products of Liraglutide: A Comparative Study of Similarity Between Originator and Analogue Version by Liquid Chromatography–Mass Spectrometry Enthalten in International journal of peptide research and therapeutics Bd. 30, 24.4.2024, Nr. 3, date:5.2024: 1-13
	113	Forty-Eight-Month Monitoring of Disease Activity in Patients with Long-Standing Rheumatoid Arthritis Treated with TNF-α Inhibitors: Time for Clinical Outcome Prediction and Biosimilar vs Biologic Originator Performance Enthalten in Clinical drug investigation Bd. 44, 31.1.2024, Nr. 3, date:3.2024: 141-148
	114	Immunogenicity, Efficacy, and Safety of Biosimilar Insulin Aspart (MYL-1601D) Compared with Originator Insulin Aspart (Novolog®) in Patients with Type 1 Diabetes After 24 Weeks: A Randomized Open-Label Study Enthalten in BioDrugs Bd. 36, 17.9.2022, Nr. 6, date:11.2022: 761-772
	115	Impact of Introducing Infliximab Biosimilars on Total Infliximab Consumption and Originator Infliximab Prices in Eight Regions: An Interrupted Time-Series Analysis Enthalten in BioDrugs Bd. 37, 23.3.2023, Nr. 3, date:5.2023: 409-420
	116	Impact of switching from the originator adalimumab to a biosimilar: a retrospective cohort study Enthalten in BMC immunology Bd. 26, 3.7.2025, Nr. 1, date:12.2025: 1-13
	117	In Vitro Biological Characterization of Recombinant Insulin Aspart from Biogenomics and Originator Insulin Aspart Enthalten in BioDrugs Bd. 37, 7.6.2023, Nr. 5, date:9.2023: 709-719
	118	Incidence of and Reasons and Determinants Associated with Retransitioning from Biosimilar Etanercept to Originator Etanercept Enthalten in BioDrugs Bd. 35, 26.10.2021, Nr. 6, date:11.2021: 765-772
	119	Interchangeability and adverse events in originator-rituximab and its biosimilar (CT-P10) among rheumatic patients: a real-life experience Enthalten in Internal and emergency medicine Bd. 18, 24.2.2023, Nr. 3, date:4.2023: 791-799
	120	Kein Nachteil durch Wechsel zwischen Biosimilar und Originator Enthalten in Hautnah / Dermatologie Bd. 34, 12.5.2018, Nr. 3, date:5.2018: 28-29

111 - 120 von 136

Alle Materialarten

Alle Kataloge/Sammlungen

Alle Standorte > Frankfurt (136)

Aktionen